Vidarbha News

Cancer Anorexia Market, Epidemiology and Market Forecast – 2030

 Breaking News
  • No posts were found

Cancer Anorexia Market, Epidemiology and Market Forecast – 2030

July 27
05:54 2021
Cancer Anorexia Market, Epidemiology and Market Forecast - 2030

DelveInsight Business Research LLP
DelveInsight’s ‘Cancer Anorexia Market Insights, Epidemiology and Market Forecast– 2030’ report delivers an in-depth understanding of the cancer anorexia, historical and forecasted epidemiology as well as the cancer anorexia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Cancer Anorexia Market Insight, Epidemiology, and Market Forecast Analysis Report

Cancer is the second leading cause of death worldwide. Toward the end of life, individuals with cancer experience a substantial symptom burden. The top three common symptoms in patients with cancer at the end of life are fatigue, pain, and anorexia (appetite loss). Anorexia is the lack or loss of appetite or desire to eat leading to reduced intake; associated with metabolic derangements, including the release of proinflammatory cytokines such as interleukin (IL)-1, IL-6, and tumor necrosis factor-alpha produced by the immune system and tumor cells. It is the most common cause of decreased nutrient intake that triggers malnutrition and muscle wasting.

How Cancer Anorexia is caused?

The causes of anorexia can be characterized by a negative protein and energy balance driven by a variable combination of reduced food intake and abnormal metabolism. It is often associated with an elevated basal metabolic rate, despite a decrease in physical activity and total energy expenditure. Muscle atrophy results from a decrease in protein synthesis and an increase in protein degradation, or a combination of both.

How Cancer Anorexia affected population?

Cancer Anorexia Epidemiology

  • The total incident cases of anorexia by cancer types in the seven major markets was estimated to be 740,055 in 2020.
  • The total incident cases of anorexia by cancer types in the 7 MM is expected to increase at a CAGR of 1.1% during the forecast period 2021–2030.
  • In the United States, the incidence population of anorexia by cancer types was 265,539 in 2020.

To know more, request sample pages @ Cancer Anorexia Market Landscape

Cancer Anorexia Market Outlook

 

  • The market size of Cancer Anorexia in the seven major markets was estimated to be USD 313.52 Million in 2020, which is expected to show a positive growth at a CAGR of 10.92% during the study period 2018–2030.
  • The United States accounts for the largest market size of USD 133.71 Million in 2020 of Cancer Anorexia throughout the study period of 2018–2030, in comparison to EU5 (Italy, Germany, France, Spain, the UK) and Japan, respectively.
  • Among the EU5 countries, Germany had the highest market size with USD 27.36 Million in 2020, while Spain had the lowest market size with USD 13.74 Million in 2020.
  • The Japan Cancer Anorexia market accounted for USD 75.10 Million in 2020.

The treatment of anorexia related to cancer focuses on improving the appetite and neutralizing the metabolic disturbances. Current pharmacological agents can be categorized as orexigenic agents (appetite stimulants), anti-catabolic (anti-metabolic and anti-cytokine) agents, and anabolic agents (primarily hormonal).

 

Progestagens (megestrol acetate and medroxyprogesterone acetate) are often used as the first-line therapy for cancer anorexia and cachexia. Additionally, the US FDA approved Megestrol to treat anorexia and weight loss in patients with AIDS in 1993. Corticosteroids, mainly dexamethasone, are widely used to improve appetite in patients with cancer anorexia, however, they are associated with significant side effects, including gastrointestinal bleeding, oral candidiasis, and proximal myopathy. Other than corticosteroids and progestogens, there are certain less frequently prescribed medications for improving cancer-related anorexia, which includes NSAIDs, Omega 3 fatty acids, and cannabis.

The current market of cancer anorexia is dominated by off-label treatments, which are not very effective in providing relief to the patients and cannot be used in the long-term because of their various side-effects. Moreover, the emerging pipeline of cancer anorexia is quite weak, with three promising lead candidates in the late and early stages of development. The candidates with promising results include Anamorelin HCl (Adlumiz, ONO-7643 and ANAM), ART27.13, and NGM120 by potential key players Helsinn Healthcare, Artelo Biosciences, and NGM Biopharmaceuticals, respectively.

 

Which are the leading companies in Cancer Anorexia market?

Positive results by major key players NGM Biopharmaceuticals, Artelo Biosciences and Helsinn Healthcare may increase market size in the coming years, assisted by an increase in Cancer Anorexia incident population pool.

Request sample pages for more information @  Cancer Anorexia Market Size 

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/